An observational study in Steatohepatitis, Nonalcoholic, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Institute of Cancer Research, United Kingdom · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.
Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 21st largest by planned enrollment of the 21 observational ones that give a count, is one of 7 that started in 2024, is one of 21 observational ones, reaches primary completion later than 3 of the 26 other live ones, and was the 119th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United Kingdom, United States, Puerto Rico
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 31 more countries
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18+ · Women only
Akero Therapeutics, Inc · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 41 · Phase 3 19 · Phase 4 4
First in 2008; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 104 across the 101 interventional studies, 153 across the 21 observational. Of the 86 that completed or were terminated, 44 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 122 have an industry lead sponsor. The 10 most frequent:
Institute of Cancer Research, United Kingdom is the lead sponsor of 113 studies on the registry; 27 are open to participants now.
Institute of Cancer Research, United Kingdom has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093346University of NottinghamThe Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2027-03-31 |
| NCT04666402Manchester University NHS Foundation TrustIntegrated Diagnostics for Early Diagnosis of Liver Disease | 2027-03-31 |
| NCT06920316St. George's Hospital, LondonDigital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | 2027-05 |
| NCT04141592Queen Mary University of LondonInvestigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease | 2027-07-31 |
| NCT06836609Regeneron PharmaceuticalsA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | 2027-08-17 |
Add all 6 to your calendar (.ics) → With an account.
Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an unwanted side effect of common cancer therapies, such as chemotherapy. Ultrasound can detect NAFLD via measurement of the backscatter coefficient (BSC). It is an attractive technique because of its low cost and availability, potentially enabling earlier detection of NAFLD in a larger population through screening. This approach has shown promise in detecting NAFLD but is limited by variability in measurement due to several factors. Measurement of the BSC requires assumptions about the nature of the tissue being measured; if these assumptions are incorrect, they can lead to inaccurate BSC measurements. To improve accuracy, an algorithm (COSIE) was developed to quantify the suitability of tissue for BSC analysis. The investigators believe COSIE will enable more reliable BSC measurements by selecting the optimal regions of tissue to measure. By measuring the BSC in the livers of healthy volunteers and patients with evidence of fatty liver, the algorithm can be evaluated against liver fat percentage values obtained from MRI imaging. This study will assess whether applying the COSIE algorithm enhances the reliability of BSC measurements, bringing them closer in quality to MRI imaging.
It is assumed that these volunteers will display a range of liver fat fractions and that there may be bias towards the low-fat fractions (\< 5%). Patients with known fatty liver are included to present a broader range of cases to consider, thereby improving the analysis. If a patient is MR scanned and it is found that they have low fat fraction, we will aim to replace them with another patient that does have a high fat fraction.
This number has been selected without a priori predictions of the expected variance in results. This study will help to determine the necessary study power required for future investigations. This population size has been selected based on practical considerations, i.e. cost of MR and length of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Volunteers:
Patients:
Exclusion Criteria:
Healthy Volunteers:
Patients:
Staff at Royal Marsden Hospital or Institute of Cancer Research
Device: Ultrasound image processing
Patients undergoing therapy/follow up for cancer with some evidence of non-alcoholic fatty liver disease.
Device: Ultrasound image processing
The COSIE study examines the coherence of ultrasound to improve the estimation of the backscatter coefficient.
Difference in backscatter coefficient
Mean difference in repeat measures of backscatter coefficient (BSC) in the liver with and without application of COSIE, across all participants and all views.
Time frame: up to 6 months
Plan to share: Yes — Anonymised ultrasound and MR images will be shared upon request.
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jun 2025, 10 months after the start.
Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 10 months is below that.
Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Institute of Cancer Research, United Kingdom →